Absolute lymphocyte count predicts efficacy of palbociclib in patients with metastatic luminal breast cancer
ALC can serve as a predictor of palbociclib efficacy in patients with metastatic ER-positive, HER2-negative breast cancer.
Authors
- Rika Kizawa (ORCID: https://orcid.org/0000-0003-1275-9228)
- Fumikata Hara (ORCID: https://orcid.org/0000-0001-8025-3494)
- Yosuke Aoyama (ORCID: https://orcid.org/0000-0003-0081-9115)
- Toshimi Takano (ORCID: https://orcid.org/0000-0002-8417-5291)
- Takayuki Ueno (ORCID: https://orcid.org/0000-0002-9080-9377)
- Yukinori Ozaki (ORCID: https://orcid.org/0000-0002-8064-648X)
- Meiko Nishimura (ORCID: https://orcid.org/0000-0002-7285-9426)
- Ippei Fukada (ORCID: https://orcid.org/0000-0001-7272-3708)
- Mari Hosonaga (ORCID: https://orcid.org/0000-0001-8525-2941)
- Takayuki Kobayashi (ORCID: https://orcid.org/0000-0001-5257-3247)
- Saori Kawai
Institutions
- Japanese Foundation For Cancer Research (JP)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1186/s12885-024-12941-z
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Japan Society for the Promotion of Science